A team at the National Health Research Institutes (NHRI) has discovered a novel orally available small molecule, DBPR728, that can cut off the nutrient supply for cancer cell growth, which can serve as a new targeted therapy drug.
The research team consists of scientists from the NHRI’s Institute of Biotechnology and Pharmaceutical Research, including Chi Ya-hui (紀雅惠), Yeh Teng-kuang (葉燈光), Chen Chiung-tong (陳炯東) and Chang Chun-ping (張竣評).
Chi told a news conference at the Ministry of Health and Welfare in Taipei yesterday that the occurrence of cancer is often caused by genetic aberrations that lead to uncontrolled cell proliferation.
Photo: Chen Yi-kuan, Taipei Times
An “oncogene” is a gene that has the potential to transform normal cells into cancerous ones through genetic aberrations — including mutation, fusion and amplification, she said.
Genetic amplification refers to an increase in the number of copies of the same gene, and studies have suggested that approximately 28 percent of cancers exhibit Myelocytomatosis (MYC) oncogene amplification, Chi said, adding that they include lung cancer, breast cancer, liver cancer and prostate cancer, as well as several other types.
For cancer cells to grow, the MYC oncoprotein functions as a transcription factor, facilitating the production of enzymes required for glycolysis (the process of breaking down glucose to produce energy), she said.
Therefore, MYC overexpression (too many copies of the MYC oncoprotein) allows cancer cells to metabolize energy in low-oxygen conditions, leading to uncontrolled cell growth and high post-operative recurrence rates, ultimately reducing overall patient survival rates, she said.
However, while there are many therapies that target specific genetic mutations in cancer cells, there are still challenges in developing drugs that target several oncogenes and their cancer-driving proteins, such as the MYC oncogene, due to the intrinsic properties of its proteins, Chi said.
In an effort to suppress MYC overexpression, Chi said the team tried to exploit its “good friend,” the enzyme Aurora kinase A, which stabilizes the MYC protein, by designing small molecules that disrupt the interaction between the two proteins, leading to MYC protein degradation.
They used the molecule DBPR728 to create an inactive oral drug that is stable in the gastrointestinal tract and can be bioconverted to become active when it reaches tumor cells, she said.
Chi said administering the oral drug to mice which have tumor cells with MYC genetic amplification and overexpression showed that the drug to can efficiently induce MYC reduction and cell apoptosis (the process of programmed cell death) in just 10 days.
The drug has obtained a patent in Taiwan and the team is applying for patents in other nations, and hopefully after it passes preclinical toxicity studies and clinical trials, it can be produced as a targeted drug for cancer treatment, she said.
The team’s findings were published in the June issue of Molecular Cancer Therapeutics, a leading journal published by the American Association for Cancer Research.
A subsidiary of a Hong Kong-based company that has lost control of two critical ports on the Panama Canal said it is seeking US$2 billion of compensation in damages from Panama over its “illegal” takeover of the ports. Panama Ports Co, a unit of Hong Kong’s CK Hutchison Holdings (長江和記實業), on Friday said in a statement that it is demanding the sum under international arbitration proceedings that it had already started. The Panamanian government last week seized control of the Balboa and Cristobal ports on each end of the Panama Canal, after the country’s Supreme Court declared earlier that a concession allowing
DETERRENCE: With 1,000 indigenous Hsiung Feng II and III missiles and 400 Harpoon missiles, the nation would boast the highest anti-ship missile density in the world With Taiwan wrapping up mass production of Hsiung Feng II and III missiles by December and an influx of Harpoon missiles from the US, Taiwan would have the highest density of anti-ship missiles in the world, a source said yesterday. Taiwan is to wrap up mass production of the indigenous anti-ship missiles by the end of year, as the Chungshan Institute of Science and Technology has been meeting production targets ahead of schedule, a defense official with knowledge of the matter said. Combined with the 400 Harpoon anti-ship missiles Taiwan expects to receive from the US by 2028, the nation would have
POSSIBILITIES EMERGE: With Taiwan’s victory and Japan’s narrow win over Australia, Taiwan now have a chance to advance if South Korea also beat the Aussies Taiwan has high hopes that the national baseball team would advance to the World Baseball Classic (WBC) quarter-finals after clinching a crucial 5-4 victory over South Korea in a nail-biting extra-inning game at the Tokyo Dome yesterday. Boosted by three home runs — two solo shots by Yu Chang (張育成) and Cheng Tsung-che (鄭宗哲) and a two-run homer by Stuart Fairchild — the triumph gave Taiwan a much-needed second victory in the five-team Pool C, where only the top two finishers would advance to the knockout stage in Miami, Florida. Entering extra innings with the game tied at four apiece, Taiwan scored
MISSION OF PEACE: The foreign minister urged Beijing to respect Taiwan’s existence as an independent nation, and work together to ensure peace and stability in the region Minister of Foreign Affairs Lin Chia-lung (林佳龍) yesterday rejected Chinese Minister of Foreign Affairs Wang Yi’s (王毅) comments about Taiwan, criticizing China as a “troublemaker” in the international community and a disruptor of cross-strait peace. Speaking at a news conference on the sidelines of the Chinese National People’s Congress, Wang said that Taiwan has always been a territory of China and that it would be impossible for it to become its own country. The “return” of Taiwan to China was the natural outcome of the Chinese people’s resistance against Japan in World War II, and that any pursuit of independence was “doomed
RSS